文献速递肝病

特利加压素在慢加急性肝衰竭合并急性肾损伤治疗中优于去甲肾上腺素

Terlipressin Is Superior to Noradrenaline in the Management of Acute Kidney Injury in Acute on Chronic Liver Failure.
PubMed 文献 · Hepatology · 2019-02-20

特利加压素组第4天和第7天应答率、HRS逆转率及28天生存率均更高,但限制用药的不良事件更多;多因素分析显示去甲肾上腺素与治疗无应答和高死亡率相关。

要点

  • 特利加压素组第4天应答率26.1% vs 去甲肾上腺素组11.7%(P=0.03),第7天应答率41.7% vs 20%(P=0.01)。
  • 特利加压素组HRS逆转率40% vs 16.7%(P=0.004),肾脏替代治疗需求56.6% vs 80%(P=0.006),28天生存率48.3% vs 20%(P=0.001)。
  • 特利加压素组限制用药的不良事件23.3% vs 去甲肾上腺素组8.3%(P=0.02),但均可逆。

核心结论

  • 在ACLF合并HRS-AKI患者中,特利加压素输注比去甲肾上腺素起效更早、应答率更高,并改善生存。

研究设计与样本

  • 开放标签随机对照试验,连续纳入ACLF合并HRS急性肾损伤患者,随机分为白蛋白联合特利加压素组(2-12 mg/天,n=60)或去甲肾上腺素组(0.5-3.0 mg/小时,n=60)。

主要发现

  • 特利加压素组第4天应答率26.1% vs 去甲肾上腺素组11.7%(P=0.03),第7天应答率41.7% vs 20%(P=0.01)。
  • 特利加压素组HRS逆转率40% vs 去甲肾上腺素组16.7%(P=0.004),肾脏替代治疗需求56.6% vs 80%(P=0.006),28天生存率48.3% vs 20%(P=0.001)。
  • 特利加压素组限制用药的不良事件23.3% vs 去甲肾上腺素组8.3%(P=0.02),但均可逆。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Hepatorenal syndrome (HRS) carries a high short-term mortality in patients with cirrhosis and acute on chronic liver failure (ACLF). Terlipressin and noradrenaline are routinely used in cirrhosis with HRS and have been found to be equally effective. There are no data comparing the efficacy of terlipressin with noradrenaline in ACLF patients with HRS. In an open-label, randomized controlled trial (RCT), consecutive patients with ACLF diagnosed with HRS acute kidney injury (AKI) were randomized to albumin with infusion of terlipressin (2-12 mg/day; n = 60) or noradrenaline (0.5-3.0 mg/h; n = 60). Response to treatment, course of AKI, and outcome were studied. Baseline characteristics, including AKI stage and sepsis-related HRS-AKI, were comparable between groups. Compared to noradrenaline, terlipressin achieved greater day 4 (26.1% vs. 11.7%; P = 0.03) and day 7 (41.7% vs. 20%; P = 0.01) response. Reversal of HRS was also better with terlipressin (40% vs. 16.7%; P = 0.004), with a significant reduction in the requirement of renal replacement therapy (RRT; 56.6% vs. 80%; P = 0.006) and improved 28-day survival (48.3% vs. 20%; P = 0.001). Adverse events limiting use of drugs were higher with terlipressin than noradrenaline (23.3% vs. 8.3%; P = 0.02), but were reversible. On multivariate analysis, high Model for End-Stage Liver Disease (MELD; odds ratio [OR], 1.10; confidence interval [CI] = 1.009-1.20; P = 0.03) and noradrenaline compared to terlipressin (OR, 3.05; CI = 1.27-7.33; P = 0.01) predicted nonresponse to therapy. Use of noradrenaline compared to terlipressin was also predictive of higher mortality (hazard ratio [HR], 2.08; CI = 1.32-3.30; P = 0.002). Conclusion: AKI in ACLF carries a high mortality. Infusion of terlipressin gives earlier and higher response than noradrenaline, with improved survival in ACLF patients with HRS-AKI.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Arora V, Maiwall R, Rajan V, et al. Terlipressin Is Superior to Noradrenaline in the Management of Acute Kidney Injury in Acute on Chronic Liver Failure. Hepatology. 2019. PMID: 30076614. doi:10.1002/hep.30208

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。